



## PREFERRED SPECIALTY MANAGEMENT POLICY

**POLICY:** Multiple Sclerosis Preferred Specialty Management Policy

<b>Cladribine Products (Oral)</b>
• Mavenclad® (cladribine tablets – EMD Serono, generic)
<b>Fumarate Products (Oral)</b>
• Tecfidera® (dimethyl fumarate delayed-release capsules – Biogen, generic)
<b>Glatiramer Products (Self-Injectable)</b>
• Copaxone® (glatiramer subcutaneous injection – Teva, generic)
<b>Pyrimidine Synthesis Inhibitor (Oral)</b>
• Aubagio® (teriflunomide tablets – Genzyme/Sanofi, generic)
<b>Sphingosine 1-Phosphate Receptor Modulator</b>
• Gilenya® (fingolimod capsules – Novartis, generic)
• Ponvory® (ponesimod tablets – Vanda)
• Tascenso ODT® (fingolimod orally disintegrating tablets – Handa/Cycle)

**REVIEW DATE:** 07/23/2025; selected revision 02/25/2026

### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## Cigna National Formulary Coverage:

### OVERVIEW

This Preferred Specialty Management policy involves the use of selected self-administered injectable products and selected oral disease-modifying agents used

for **multiple sclerosis**.<sup>1-10</sup> All products are indicated for use in adults. Of note, fingolimod and Tascenso ODT are the only agents specifically indicated for children  $\geq 10$  years of age for the treatment of relapsing forms of multiple sclerosis.<sup>5,8</sup>

## **POLICY STATEMENT**

The Multiple Sclerosis Preferred Specialty Management Program has been developed to encourage the use of the Preferred Products (generic glatiramer injection and generic dimethyl fumarate delayed-release capsules). For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria. The Program also directs the patient to try both Preferred Products prior to the approval of a Non-Preferred Product. Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). All approvals are provided for 1 year. If a patient requesting a Non-Preferred Product meets the standard *Prior Authorization Policy* criteria but has not tried both Preferred Products, an offer to review for the Preferred Products will be made.

The Tecfidera (Brand) Preferred Specialty Management Program has been developed to encourage the use of generic dimethyl fumarate delayed-release capsules. For all medications (Preferred and Non-Preferred) the patient is required to meet the respective standard *Prior Authorization Policy* criteria. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). All approvals are provided for 1 year. If a patient requesting the Non-Preferred Product (Tecfidera [brand]) meets the standard *Prior Authorization Policy* criteria but has not tried the Preferred Product, an offer to review for the Preferred Product will be made.

The S1P Preferred Specialty Management Program has been developed to encourage the use of the Preferred Products (generic dimethyl fumarate delayed-release capsules and generic fingolimod capsules). For all medications (Preferred and Non-Preferred) the patient is required to meet the respective standard *Prior Authorization Policy* criteria. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). All approvals are provided for 1 year. If a patient requesting a Non-Preferred Product meets the standard *Prior Authorization Policy* criteria but has not tried the Preferred Products, an offer to review for the Preferred Products will be made.

The Aubagio Preferred Specialty Management Program has been developed to encourage the use of the Preferred Products (generic glatiramer injection, generic dimethyl fumarate delayed-release capsules, generic fingolimod capsules, and generic teriflunomide tablets). For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). All approvals are provided for 1 year. If a patient requesting a Non-Preferred Product meets the standard *Prior Authorization Policy* criteria but has not tried the Preferred Products, an offer to review for the Preferred Products will be made.

The Mavenclad (Brand) Preferred Specialty Management Program has been developed to encourage the use of generic cladribine tablets. For all medications (Preferred and Non-Preferred) the patient is required to meet the respective standard *Prior Authorization Policy* criteria. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). All approvals are provided for 1 year. If a patient requesting the Non-Preferred Product (Mavenclad [brand]) meets the standard *Prior Authorization Policy* criteria but has not tried the Preferred Product, approval for the Preferred Product will be authorized.

**Documentation:** Documentation is required for use of certain products as noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to chart notes, prescription claims records, prescription receipts, magnetic resonance imaging reports, and/or other information. All documentation must include patient-specific identifying information.

#### **Multiple Sclerosis Preferred Specialty Management Program**

**Preferred Products:** generic glatiramer injection and generic dimethyl fumarate delayed-release capsules

**Non-Preferred Products:** Copaxone

#### **Tecfidera (Brand) Preferred Specialty Management Program**

**Preferred Product:** generic dimethyl fumarate delayed-release capsules

**Non-Preferred Product:** Tecfidera (brand)

#### **S1P Preferred Specialty Management Program**

**Preferred Products:** generic fingolimod capsules and generic dimethyl fumarate delayed-release capsules

**Non-Preferred Products:** Gilenya (brand), Tascenso ODT, Ponvory

#### **Aubagio Preferred Specialty Management Program**

**Preferred Products:** generic teriflunomide tablets and generic glatiramer injection and generic dimethyl fumarate delayed-release capsules and generic fingolimod capsules

**Non-Preferred Product:** Aubagio (brand)

#### **Mavenclad (Brand) Preferred Specialty Management Program**

**Preferred Product:** generic cladribine tablets

**Non-Preferred Product:** Mavenclad (brand)

***Multiple Sclerosis Preferred Specialty Management Policy non-preferred product(s) is(are) covered as medically necessary when the following non-preferred product exception criteria is(are) met. Any other exception is considered not medically necessary.***

## NON-PREFERRED PRODUCT EXCEPTION CRITERIA

### I. Multiple Sclerosis Preferred Specialty Management Program

Non-Preferred Product	Exception Criteria
Copaxone 20 mg/mL and 40 mg/mL	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A <u>and</u> B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis – Glatiramer Products Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets BOTH of the following (i <u>and</u> ii):</p> <p><b>i.</b> Patient meets ONE of the following (a <u>or</u> b):</p> <p><b>a)</b> Patient has been established on a glatiramer product for ≥ 120 days; OR</p> <p><b>b)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patients has tried generic dimethyl fumarate delayed-release capsules <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance, according to the prescriber <b>[documentation required]</b>; AND</p> <p><u>Note:</u> Prior use of Tecfidera, Bafiertam, or Vumerity with inadequate efficacy or significant intolerance (according to the prescriber) also counts.</p> <p><b>ii.</b> Patient meets BOTH of the following (a <u>and</u> b):</p> <p><b>a)</b> Patient has tried generic glatiramer injection <b>[documentation required]</b>; AND</p> <p><b>b)</b> Patient cannot continue to use generic glatiramer injection due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the brand and the bioequivalent generic product which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>.</p> <p><b>2.</b> If the patient meets the standard <i>Multiple Sclerosis – Glatiramer Prior Authorization Policy</i> criteria, but does not meet criterion 1B, offer to review for the Preferred Product(s).</p>

## II. Tecfidera (Brand) Preferred Specialty Management Program

Non-Preferred Product	Exception Criteria
Tecfidera (brand)	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A and B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis – Dimethyl Fumarate Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets BOTH of the following (i and ii):</p> <ul style="list-style-type: none"> <li><b>i.</b> Patient has tried generic dimethyl fumarate delayed-release capsules <b>[documentation required]</b>; AND</li> <li><b>ii.</b> Patient cannot continue to use generic dimethyl fumarate delayed-release capsules due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>.</li> </ul> <p><b>2.</b> If the patient meets the standard <i>Multiple Sclerosis – Dimethyl Fumarate Prior Authorization Policy</i> criteria, but does not meet criterion 1B, offer to review for the Preferred Product.</p>

### III. S1P Preferred Specialty Management Program

Non-Preferred Product	Exception Criteria
Ponvory	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A <u>and</u> B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis – Ponvory Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets ONE of the following (i <u>or</u> ii):</p> <p><b>i.</b> Patient has been established on Ponvory for <math>\geq</math> 120 days; OR</p> <p><b>ii.</b> Patient meets BOTH of the following (a <u>and</u> b):</p> <p><b>a)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic dimethyl fumarate delayed-release capsules <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance according to the prescriber <b>[documentation required]</b>; AND  <u>Note:</u> Prior use of Tecfidera, Bafiertam, or Vumerity with inadequate efficacy or significant intolerance (according to the prescriber) also counts <b>[documentation required]</b>.</p> <p><b>b)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic fingolimod capsules <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance according to the prescriber <b>[documentation required]</b>.  <u>Note:</u> Prior use of Gilenya (brand) or Tascenso ODT with inadequate efficacy or significant intolerance (according to the prescriber) also counts <b>[documentation required]</b>.</p> <p><b>2.</b> If the patient meets the standard <i>Multiple Sclerosis – Ponvory Prior Authorization Policy</i> criteria, but does not meet criterion 1B, offer to review for the Preferred Product(s).</p>

Non-Preferred Product	Exception Criteria
Gilenya (brand)	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A <u>and</u> B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis – Fingolimod Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets BOTH of the following (i <u>and</u> ii):</p> <p><b>i.</b> Patient meets ONE of the following (a, b, <u>or</u> c):</p> <p><b>a)</b> Patient has been established on Gilenya (brand or generic) for <math>\geq</math> 120 days; OR</p> <p><b>b)</b> Patient is <math>\geq</math> 10 to <math>&lt;</math> 18 years of age; OR</p> <p><b>c)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic dimethyl fumarate delayed-release capsules <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance according to the prescriber <b>[documentation required]</b>; AND</p> <p><u>Note:</u> Prior use of Tecfidera, Bafiertam, or Vumerity with inadequate efficacy or significant intolerance (according to the prescriber) also counts <b>[documentation required]</b>.</p> <p><b>ii.</b> Patient meets BOTH of the following (a <u>and</u> b):</p> <p><b>a)</b> Patient has tried generic fingolimod capsules <b>[documentation required]</b>; AND</p> <p><b>b)</b> Patient cannot continue to use generic fingolimod capsules due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>.</p> <p><b>2.</b> If the patient meets the standard <i>Multiple Sclerosis – Fingolimod Prior Authorization Policy</i> criteria, but does not meet criterion 1B, offer to review for the Preferred Product(s).</p>

Non-Preferred Product	Exception Criteria
Tascenso ODT	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A and B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis – Tascenso ODT Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets BOTH of the following (i and ii):</p> <p><b>i.</b> Patient meets ONE of the following (a, b, c, or d):</p> <p><b>a)</b> Patient cannot swallow or has difficulty swallowing tablets or capsules; OR</p> <p><b>b)</b> Patient has been established on Tascenso ODT for <math>\geq</math> 120 days; OR</p> <p><b>c)</b> Patient is <math>\geq</math> 10 to <math>&lt;</math> 18 years of age; OR</p> <p><b>d)</b> Patient meets BOTH of the following [(1) and (2)]:</p> <p><b>(1)</b> Patient has tried generic dimethyl fumarate delayed-release capsules <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance according to the prescriber <b>[documentation required]</b>; AND  <u>Note:</u> Prior use of Tecfidera, Bafiertam, or Vumerity with inadequate efficacy or significant intolerance (according to the prescriber) also counts <b>[documentation required]</b>.</p> <p><b>ii.</b> Patient meets ONE of the following (a or b):</p> <p><b>a)</b> Patient meets BOTH of the following (i and ii):</p> <p><b>i.</b> Patient has tried generic fingolimod capsules <b>[documentation required]</b>; AND</p> <p><b>ii.</b> Patient cannot continue to use generic fingolimod capsules due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>.</p> <p><b>b)</b> Patient cannot swallow or has difficulty swallowing tablets or capsules.</p> <p><b>2.</b> If the patient meets the standard <i>Multiple Sclerosis – Fingolimod Prior Authorization Policy</i> criteria, but does not meet criterion 1B, offer to review for the Preferred Product(s).</p>

#### IV. Aubagio Preferred Specialty Management Program

Non-Preferred Product	Exception Criteria
Aubagio (brand)	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A <u>and</u> B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis – Teriflunomide Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets ONE the following (i <u>or</u> ii):</p> <p><b>i.</b> Patient meets BOTH of the following (a <u>and</u> b):</p> <p><b>a)</b> Patient has been established on Aubagio (brand or generic) for ≥ 120 days; AND</p> <p><b>b)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic teriflunomide tablets <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient cannot continue to use generic teriflunomide tablets due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>; OR</p> <p><b>ii.</b> Patient meets ALL of the following (a, b, c, <u>and</u> d):</p> <p><b>a)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic dimethyl fumarate delayed-release capsules <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance, according to the prescriber <b>[documentation required]</b>; AND  <u>Note:</u> Prior use of Tecfidera, Bafiertam, or Vumerity with inadequate efficacy or significant intolerance (according to the prescriber) also counts.</p> <p><b>b)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic glatiramer injection <b>[documentation required]</b>; AND</p> <p><b>(2)</b> Patient has experienced inadequate efficacy or significant intolerance, according to the prescriber <b>[documentation required]</b>; AND  <u>Note:</u> Prior use of Copaxone or Glatopa with inadequate efficacy or significant intolerance (according to the prescriber) also counts.</p> <p><b>c)</b> Patient meets BOTH of the following [(1) <u>and</u> (2)]:</p> <p><b>(1)</b> Patient has tried generic fingolimod capsules <b>[documentation required]</b>; AND</p>

Non-Preferred Product	Exception Criteria
	<p>(2) Patient has experienced inadequate efficacy or significant intolerance, according to the prescriber; AND</p> <p>d) Patient meets BOTH of the following [(1) <u>and</u> (2)]</p> <p>(1) Patient has tried generic teriflunomide tablets <b>[documentation required]</b>; AND</p> <p>(2) Patient cannot continue to use generic teriflunomide tablets due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>.</p> <p>2. If the patient meets the standard <i>Multiple Sclerosis – Teriflunomide Prior Authorization Policy</i> criteria, but does not meet criterion 1B, offer to review for the Preferred Product(s).</p>

## V. Mavenclad (Brand) Preferred Specialty Management Program

Non-Preferred Product	Exception Criteria
Mavenclad (brand)	<p><b>1.</b> Approve for 1 year if the patient meets BOTH of the following (A and B):</p> <p><b>A)</b> Patient meets the standard <i>Multiple Sclerosis (Oral – Other) – Cladribine Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient meets BOTH of the following (i and ii):</p> <p><b>i.</b> Patient has tried generic cladribine tablets <b>[documentation required]</b>; AND</p> <p><b>ii.</b> Patient cannot continue to use generic cladribine tablets due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction <b>[documentation required]</b>.</p> <p><b>2.</b> If the patient meets the standard <i>Multiple Sclerosis (Oral – Other) – Cladribine Prior Authorization Policy</i> criteria, but does not meet criterion 1B, approve generic cladribine tablets.</p>

### REFERENCES

1. Copaxone® subcutaneous injection [prescribing information]. Parsippany, NJ: Teva; January 2025.
2. Glatopa® subcutaneous injection [prescribing information]. Princeton, NJ: Sandoz; February 2025.
3. Glatiramer acetate subcutaneous injection (20 mg/mL) [prescribing information]. Morgantown, WV: Mylan; February 2025.
4. Glatiramer acetate subcutaneous injection (40 mg/mL) [prescribing information]. Morgantown, WV: Mylan; February 2025.
5. Gilenya® capsules [prescribing information]. East Hanover, NJ: Novartis; June 2024.
6. Aubagio® tablets [prescribing information]. Cambridge, MA: Genzyme/Sanofi; June 2024.
7. Tecfidera® delayed-release capsules [prescribing information]. Cambridge, MA: Biogen; March 2024.
8. Tascenso ODT™ [prescribing information]. Cambridge, UK and San Jose, CA: Cycle/Handa; January 2025.
9. Ponvory® tablets [prescribing information]. Washington, DC: Vanda; October 2024.
10. Mavenclad® tablets [prescribing information]. Rockland, MA: EMD Serono; May 2024.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Selected Revision	<p><b>Avonex, Bafiertam, Betaseron, Glatopa, Kesimpta, Mavenclad, Mayzent, Plegridy, Ponvory, Rebif, Vumerity, and Zeposia:</b> These agents were removed from the Multiple Sclerosis Preferred Specialty Management Program as Non-Preferred Products and related exception criteria were deleted.</p> <p><b>Copaxone:</b> The exception criteria were revised due to changes in the Preferred Products. For the Multiple Sclerosis Preferred Specialty Management Program, previously, a patient was required to try one of the following: generic glatiramer injection, generic dimethyl fumarate delayed-release capsules, generic fingolimod capsules, or generic teriflunomide tablets. Generic fingolimod capsules and generic teriflunomide tablets were removed as Preferred Products. Now, a patient is required to try both Preferred Products (generic glatiramer injection AND generic dimethyl fumarate delayed-release capsules); documentation was added for both of these trials. For the generic dimethyl fumarate delayed-release capsules, documentation has to be provided that the patient has experienced inadequate efficacy or significant intolerance, according to the prescriber. Also, for the trial of generic glatiramer injection, documentation has to be provided that the patient cannot continue to use generic glatiramer injection due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the brand and the bioequivalent generic product which, per the prescriber, would result in a significant allergy or serious adverse reaction. Exceptions were added for a patient who has been established on a glatiramer product for <math>\geq 120</math> days that a trial of generic dimethyl fumarate delayed-release capsules are not required. Exception criteria regarding generic fingolimod and generic teriflunomide were deleted.</p> <p><b>Extavia:</b> The exception criteria were revised due to changes in the Preferred Products. For the Multiple Sclerosis Preferred Specialty Management Program, previously, a patient was required to try one of the following: generic glatiramer injection, generic dimethyl fumarate delayed-release capsules, generic fingolimod capsules, or generic teriflunomide tablets. Generic fingolimod capsules and generic teriflunomide tablets were removed as Preferred Products. Now, a patient is required to try both Preferred Products (generic glatiramer injection AND generic dimethyl fumarate delayed-release capsules); documentation was added for both of these trials. Also, for both Preferred Products, documentation has to be provided that the patient has experienced inadequate efficacy or significant intolerance, according to the prescriber. Exception criteria regarding generic fingolimod and generic teriflunomide were deleted.</p>	03/27/2024 (effective 05/01/2024)
Annual Revision	No criteria changes.	10/09/2024
Selected Revision	<p>The name of the Fingolimod Preferred Specialty Management Program was changed to the S1P Preferred Specialty Management Program. In addition, the following changes were made:</p> <p><b>Ponvory:</b> Ponvory was added as a Non-Preferred Product to the S1P Preferred Specialty Management Program. Exception criteria were added.</p> <p><b>Gilenya (brand):</b> Regarding the trial of dimethyl fumarate delayed-release tablets, the exception was removed that prior use of glatiramer injection (brand or generic) with inadequate efficacy or</p>	01/08/2025

	<p>significant intolerance (according to the prescriber) also counts [documentation required].</p> <p><b>Tascenso ODT:</b> Regarding the trial of dimethyl fumarate delayed-release tablets, the exception was removed that prior use of glatiramer injection (brand or generic) with inadequate efficacy or significant intolerance (according to the prescriber) also counts [documentation required].</p>	
Selected Revision	<p>In the S1P Preferred Specialty Management Program, criteria for Ponvory were clarified that a trial of generic dimethyl fumarate delayed-release capsules AND generic fingolimod capsules are required (along with inadequate efficacy or significant intolerance, according to the prescriber). Patients established on Ponvory for <math>\geq</math> 120 days do not have to meet this requirement.</p>	01/22/2025

### HISTORY (CONTINUED)

Type of Revision	Summary of Changes	Review Date
Early Annual Revision	<p><b>Extavia:</b> This agent was removed from the policy, as well as the appendix. It is no longer listed as a Non-Preferred Product in the Multiple Sclerosis Preferred Specialty Management Program; the related criteria were also deleted.</p> <p><b>Gilenya:</b> The criteria that allowed exceptions for a patient who has, according to the prescriber, highly active or aggressive multiple sclerosis were deleted. This was defined by meeting one of the following: 1) Patient has demonstrated rapidly advancing deterioration(s) in physical functioning [documentation required] with a Note that examples include loss of mobility, lower levels of ambulation, and/or severe changes in strength or coordination; OR 2) Disabling relapse(s) with suboptimal response to systemic corticosteroids [documentation required]; OR 3) Magnetic resonance imaging (MRI) suggests highly active or aggressive multiple sclerosis [documentation required] with a note that examples include new, enlarging, or a high burden of T2 lesions or gadolinium enhancing lesions; OR 4) Manifestations of multiple sclerosis related cognitive impairment [documentation required].</p> <p><b>Tascenso ODT:</b> The criteria that allowed exceptions for a patient who has, according to the prescriber, highly active or aggressive multiple sclerosis were deleted. This was defined by meeting one of the following: 1) Patient has demonstrated rapidly advancing deterioration(s) in physical functioning [documentation required] with a Note that examples include loss of mobility, lower levels of ambulation, and/or severe changes in strength or coordination; OR 2) Disabling relapse(s) with suboptimal response to systemic corticosteroids [documentation required]; OR 3) Magnetic resonance imaging (MRI) suggests highly active or aggressive multiple sclerosis [documentation required] with a note that examples include new, enlarging, or a high burden of T2 lesions or gadolinium enhancing lesions; OR 4) Manifestations of multiple sclerosis related cognitive impairment [documentation required].</p>	07/23/2025
Selected Revision	<p><b>Policy Statement:</b> The Policy Statement was updated to reflect the addition of the Mavenclad (Brand) Preferred Specialty Management Program.</p> <p><b>Mavenclad (Brand) Preferred Specialty Management Program:</b> A new Preferred Specialty Management Program was added which directs requests for brand Mavenclad to generic cladribine tablets. Patients are required to meet the standard <i>Multiple Sclerosis (Oral – Other) – Cladribine Prior Authorization Policy</i> criteria for both generic cladribine requests and brand</p>	02/25/2026 (effective 05/11/2026)

	<p>Mavenclad requests. Additionally, if the request is for brand Mavenclad, documentation is required that the patient has tried generic cladribine tablets and cannot continue to use generic cladribine tablets due to a formulation difference in the inactive ingredient(s) [e.g., differences in dyes, fillers, preservatives] between the Brand and the bioequivalent generic which, per the prescriber, would result in a significant allergy or serious adverse reaction.</p>	
--	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.